HomeCompareRMD vs LRCX

RMD vs LRCX: Dividend Comparison 2026

RMD yields 1.06% · LRCX yields 0.51%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LRCX wins by $454.6K in total portfolio value· pulled ahead in Year 3
10 years
RMD
RMD
● Live price
1.06%
Share price
$220.03
Annual div
$2.33
5Y div CAGR
35.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.7K
Annual income
$3,288.25
Full RMD calculator →
LRCX
LRCX
● Live price
0.51%
Share price
$199.93
Annual div
$1.01
5Y div CAGR
97.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$486.3K
Annual income
$337,677.40
Full LRCX calculator →

Portfolio growth — RMD vs LRCX

📍 LRCX pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRMDLRCX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RMD + LRCX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RMD pays
LRCX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RMD
Annual income on $10K today (after 15% tax)
$90.01/yr
After 10yr DRIP, annual income (after tax)
$2,795.01/yr
LRCX
Annual income on $10K today (after 15% tax)
$42.94/yr
After 10yr DRIP, annual income (after tax)
$287,025.79/yr
At 15% tax rate, LRCX beats the other by $284,230.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RMD + LRCX for your $10,000?

RMD: 50%LRCX: 50%
100% LRCX50/50100% RMD
Portfolio after 10yr
$259.0K
Annual income
$170,482.82/yr
Blended yield
65.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on LRCX right now

RMD
Analyst Ratings
16
Buy
14
Hold
5
Sell
Consensus: Buy
Price Target
$295.88
+34.5% upside vs current
Range: $265.00 — $345.00
Altman Z
11.6
Piotroski
7/9
LRCX
Analyst Ratings
38
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$267.50
+33.8% upside vs current
Range: $127.00 — $325.00
Altman Z
17.9
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RMD buys
0
LRCX buys
4
PoliticianChamberTickerTypeAmountDate
David Taylor🏢 House$LRCX▲ Buy$1,001 - $15,0002026-03-12
David Taylor🏢 House$LRCX▼ Sell$1,001 - $15,0002026-02-26
David Taylor🏢 House$LRCX▼ Sell$1,001 - $15,0002026-02-26
Tony Wied🏢 House$LRCX▼ Sell$50,001 - $100,0002026-02-12
Tony Wied🏢 House$LRCX▼ Sell$50,001 - $100,0002026-02-09
Tony Wied🏢 House$LRCX▼ Sell$50,001 - $100,0002026-02-03
Cleo Fields🏢 House$LRCX▲ Buy$15,001 - $50,0002026-02-03
David Taylor🏢 House$LRCX▼ Sell$1,001 - $15,0002026-01-16
John Boozman🏛 Senate$LRCX▼ Sell$1,001 - $15,0002026-01-08
John Boozman🏛 Senate$LRCX▼ Sell$1,001 - $15,0002026-01-08
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRMDLRCX
Forward yield1.06%0.51%
Annual dividend / share$2.33$1.01
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR35.9%97.1%
Portfolio after 10y$31.7K$486.3K
Annual income after 10y$3,288.25$337,677.40
Total dividends collected$10.4K$453.2K
Payment frequencyquarterlyquarterly
SectorHealthcareTechnology
Analyst consensusBuyBuy
Analyst price target$295.88$267.50

Year-by-year: RMD vs LRCX ($10,000, DRIP)

YearRMD PortfolioRMD Income/yrLRCX PortfolioLRCX Income/yrGap
1$10,844$143.91$10,800$99.57+$44.00RMD
2$11,801$198.21$11,754$198.08+$47.00RMD
3← crossover$12,901$273.96$12,973$397.11$72.00LRCX
4$14,185$380.39$14,689$807.41$504.00LRCX
5$15,709$531.20$17,401$1,683.97$1.7KLRCX
6$17,556$747.16$22,294$3,674.72$4.7KLRCX
7$19,845$1,060.53$32,527$8,672.33$12.7KLRCX
8$22,757$1,522.63$58,111$23,307.38$35.4KLRCX
9$26,567$2,217.64$138,882$76,703.10$112.3KLRCX
10$31,715$3,288.25$486,281$337,677.40$454.6KLRCX

RMD vs LRCX: Complete Analysis 2026

RMDHealthcare

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Full RMD Calculator →

LRCXTechnology

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products. It also provides SPEED gapfill high-density plasma chemical vapor deposition products; and Striker single-wafer atomic layer deposition products for dielectric film solutions. In addition, the company offers Flex for dielectric etch applications; Kiyo for conductor etch applications; Syndion for through-silicon via etch applications; and Versys metal products for metal etch processes. Further, it provides Coronus bevel clean products to enhance die yield; Da Vinci, DV-Prime, EOS, and SP series products to address various wafer cleaning applications; and Metryx mass metrology systems for high precision in-line mass measurement in semiconductor wafer manufacturing. The company sells its products and services to semiconductors industry in the United States, China, Europe, Japan, Korea, Southeast Asia, Taiwan, and internationally. Lam Research Corporation was incorporated in 1980 and is headquartered in Fremont, California.

Full LRCX Calculator →
📬

Get this RMD vs LRCX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RMD vs SCHDRMD vs JEPIRMD vs ORMD vs KORMD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.